181 related articles for article (PubMed ID: 35109816)
21. Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy.
White CD; Stewart AJ; Lu ZL; Millar RP; Morgan K
Neuroendocrinology; 2008; 88(2):67-79. PubMed ID: 18309229
[TBL] [Abstract][Full Text] [Related]
22. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis.
Gautam P; Nair SC; Gupta MK; Sharma R; Polisetty RV; Uppin MS; Sundaram C; Puligopu AK; Ankathi P; Purohit AK; Chandak GR; Harsha HC; Sirdeshmukh R
PLoS One; 2012; 7(9):e46153. PubMed ID: 23029420
[TBL] [Abstract][Full Text] [Related]
23. Gene expression of gonadotropin-releasing hormone and its receptor in rat pancreatic cancer cell lines.
Wang L; Xie LP; Zhang RQ
Endocrine; 2001 Apr; 14(3):325-8. PubMed ID: 11444428
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma.
Chen J; Liu Y; Lan J; Liu H; Tang Q; Li Z; Qiu X; Hu W; Xie J; Feng Y; Qin L; Zhang X; Liu J; Chen L
CNS Neurosci Ther; 2024 Jun; 30(6):e14802. PubMed ID: 38887185
[TBL] [Abstract][Full Text] [Related]
26. Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunity.
Altinoz MA; Ucal Y; Yilmaz MC; Kiris İ; Ozisik O; Sezerman U; Ozpinar A; Elmaci İ
Cancer Med; 2020 Aug; 9(16):5767-5780. PubMed ID: 32590878
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation.
Bahk JY; Kim MO; Park MS; Lee HY; Lee JH; Chung BC; Min SK
Urol Int; 2008; 80(4):431-8. PubMed ID: 18587256
[TBL] [Abstract][Full Text] [Related]
28. Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of alpha3 integrin and MMP-2 expression and activity.
Moretti RM; Montagnani Marelli M; Mai S; Limonta P
Int J Oncol; 2008 Aug; 33(2):405-13. PubMed ID: 18636163
[TBL] [Abstract][Full Text] [Related]
29. Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells.
Bahk JY; Hyun JS; Lee H; Kim MO; Cho GJ; Lee BH; Choi WS
Urol Res; 1998; 26(4):259-64. PubMed ID: 9759999
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
31. The lncRNA RP3-439F8.1 promotes GBM cell proliferation and progression by sponging miR-139-5p to upregulate NR5A2.
Qi J; Pan L; Yu Z; Ni W
Pathol Res Pract; 2021 Jul; 223():153319. PubMed ID: 33991848
[TBL] [Abstract][Full Text] [Related]
32. Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells.
Kang SK; Choi KC; Tai CJ; Auersperg N; Leung PC
Endocrinology; 2001 Feb; 142(2):580-8. PubMed ID: 11159828
[TBL] [Abstract][Full Text] [Related]
33. Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats.
Zapatero-Caballero H; Sanchez-Franco F; Guerra-Perez N; Fernandez-Mendez C; Fernandez-Vazquez G
Biol Reprod; 2003 May; 68(5):1764-70. PubMed ID: 12606421
[TBL] [Abstract][Full Text] [Related]
34. Label-free quantitative proteomics unravels the importance of RNA processing in glioma malignancy.
Bi B; Li F; Guo J; Li C; Jing R; Lv X; Chen X; Wang F; Azadzoi KM; Wang L; Liu Y; Yang JH
Neuroscience; 2017 May; 351():84-95. PubMed ID: 28341197
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
Wang Y; Matsuo H; Kurachi O; Maruo T
Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics and machine learning methodologies to identify the effects of central nervous system disorders on glioblastoma progression.
Rahman MH; Rana HK; Peng S; Hu X; Chen C; Quinn JMW; Moni MA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33406529
[TBL] [Abstract][Full Text] [Related]
38. mRNA expression of gonadotropin-releasing hormones (GnRHs) and GnRH receptor in goldfish.
Yu KL; He ML; Chik CC; Lin XW; Chang JP; Peter RE
Gen Comp Endocrinol; 1998 Dec; 112(3):303-11. PubMed ID: 9843636
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.
Wu HM; Wang HS; Huang HY; Lai CH; Lee CL; Soong YK; Leung PC
BMC Cancer; 2013 Jun; 13():300. PubMed ID: 23786715
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LbetaT2 mouse pituitary gonadotroph tumor cell line.
Hamid T; Malik MT; Millar RP; Kakar SS
Int J Oncol; 2008 Nov; 33(5):1055-64. PubMed ID: 18949369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
